<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827043</url>
  </required_header>
  <id_info>
    <org_study_id>Quadratuslumborum block &amp; TPVB</org_study_id>
    <nct_id>NCT04827043</nct_id>
  </id_info>
  <brief_title>Quadratus Lumborum Block Versus Thoracic Paravertebral Block</brief_title>
  <official_title>Ultrasound Guided Quadratus Lumborum Block Versus Thoracic Paravertebral Block in Gynacological Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess and compare the analgesic efficacy and safety of quadratus lumbotum&#xD;
      block and paravertebral block in gynacological cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will be medically checked in the preoperative assessment clinic {history,&#xD;
      physical examination, investigations (e.g. complete blood picture, coagulation profile ,&#xD;
      liver &amp; kidney functions , ECG for patient above 40 years, chest x-ray for patients above 60&#xD;
      years and any other necessary investigations required for risky patients. ) }.&#xD;
&#xD;
      The patients will be randomly allocated into two equal groups(25 patients for each group)&#xD;
      with a computer-generated list (www.Random.org).&#xD;
&#xD;
      QLB group: will receive 0.3ml/Kg bupivacaine 0.25% ( keeping in mind not to exceed the&#xD;
      maximum recommended toxic dose of plain bupivacaine which is 2.5 mg/Kg &amp; 3mg/Kg with&#xD;
      epinephrine).&#xD;
&#xD;
      PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml,&#xD;
      yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10.&#xD;
&#xD;
        -  In the recovery room, the patients will be continuous monitored for pulse, blood&#xD;
           pressure, oxygen saturation.&#xD;
&#xD;
        -  Humidified oxygen 3L/min. by nasal prong will be delivered to all patients.&#xD;
&#xD;
        -  Portable ultrasound machine , nerve stimulator, pressure injector monitor ,resuscitation&#xD;
           equipment &amp;drugs (e.g. epinephrine, lipid emulsion ), sterile gloves and surgical towels&#xD;
           should be available.&#xD;
&#xD;
        -  Intravenous(IV) 18 gauge cannula will be inserted. Midazolam 0.02 mg/Kg will be&#xD;
           administered.&#xD;
&#xD;
      While the patients in the supine or lateral position, they will receive bilateral single&#xD;
      injection ultrasound guided QLBs under complete sterilization of the abdomen with sterile&#xD;
      solution (iodine povacryl &amp; isopropyl alcohol solution). All patients will be monitored&#xD;
      throughout the performance of the block &amp; all data will be recorded. A linear ultrasound&#xD;
      transducer probe (6-13MHZ), or curved probe (according to patients BMI). ( Sonosite M-turbo;&#xD;
      Inc., Bothell, WA, USA) in a sterile cover will be placed at the level of the anterosuperior&#xD;
      iliac spine and moved cranially until the three muscle layers of the abdomen will be&#xD;
      identified: external oblique, internal oblique, and transversus abdominis muscles. The&#xD;
      external oblique muscle will be followed posterolaterally until its posterior border&#xD;
      visualize (hook sign) leaving underneath the internal oblique muscle, like a roof over the QL&#xD;
      muscle. The probe will be tilted down to identify a bright hyperechoic line that corresponded&#xD;
      with the intermediate layer of the thoracolumber fascia(Blanco et al.,2015).&#xD;
&#xD;
      A 21 gauge blunt, insulated, echogenic needle will be inserted in plane . The optimal point&#xD;
      of injection will be determined using hydrodissection (3-5 mL normal saline). The site of the&#xD;
      needle will be confirmed in place by ultrasound guided, nerve stimulator (B- Braun) &amp;&#xD;
      pressure injector monitor.&#xD;
&#xD;
      After negative aspiration, we will inject 0.3mL/Kg bupivacaine 0.25% in each side in QLB&#xD;
      group. The patients will be monitored for about 20-30 minutes before induction of anesthesia.&#xD;
&#xD;
      While the TPVB will be performed by single injections at the level of T10 vertebra. The&#xD;
      patients will be placed in the sitting position, and the spinal process of T10 will be&#xD;
      palpated. Then a linear ultrasound transducer probe (6-13 MHZ).&#xD;
&#xD;
      ( Sonosite M-turbo; Inc., Bothell, WA, USA) in a sterile cover will be placed at the&#xD;
      corresponding transverse process to be clearly visualized and the skin-transverse process&#xD;
      distance will be measured on both sides. After infiltration of the skin and subcutaneous&#xD;
      tissue with 1% lidocaine with epinephrine 5ug/ml, an 18G Touphy needle will be inserted&#xD;
      perpendicular to the skin, approximately 2.5 cm from midline, until contact with the&#xD;
      transverse process will be established ( It is important to visualize the pleura very clearly&#xD;
      at all times ). The needle will then slightly withdrawal &amp; reinserted 1-1.5 cm deeper either&#xD;
      caudally or cranially for the transverse process (TP). The site of the needle will be&#xD;
      confirmed in place by ultrasound guided, nerve stimulator (B- Braun) &amp; pressure injector&#xD;
      monitor.&#xD;
&#xD;
      After careful aspiration, patients will be received a slow injection of 0.25mL/Kg/side of&#xD;
      0.375% bupivacaine with epinephrine 5ug/ml at the level of T10. The patients will be&#xD;
      monitored for about 30 minutes before induction of anesthesia. Induction of general&#xD;
      anesthesia will be done.&#xD;
&#xD;
      After full awakening from anesthesia, the patient will be transferred to the recovery room.&#xD;
      In the recovery room, the patient will be continuous monitored &amp; humidified oxygen will be&#xD;
      applied for about 1 hour. Then a standardized analgesic regimen consisting of regular IV/oral&#xD;
      paracetamol 1g every 6 hours combined with PCA morphine (on demand) will be initiated.&#xD;
      Patients required additional analgesia will be received IV ketorolac(15-30mg).&#xD;
&#xD;
      A trained anesthetist not involved in the study &amp; blinded to the patient group will measure&#xD;
      the VAS, morphine requirements &amp; patient satisfaction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective randomized comparative study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>After approval of The InstitutionalEthics Committee of The National Cancer Institute ,Cairo University, 50 patients scheduled for gynacological cancer surgery will be enrolled in this study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analogue scale</measure>
    <time_frame>Baseline pain till first 24 hours postoperative</time_frame>
    <description>Pain score will be measured according to severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine demands postoperative</measure>
    <time_frame>First 24 hours postoperative</time_frame>
    <description>The amount of morphine required to relieve pain will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>First 24 hours postoperative</time_frame>
    <description>Patient satisfaction measured by visual analogue score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Postoperative Analgesia</condition>
  <arm_group>
    <arm_group_label>Quadratus lumborum block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QLB group: will receive 0.3ml/Kg bupivacaine 0.25% ( keeping in mind not to exceed the maximum recommended toxic dose of plain bupivacaine which is 2.5 mg/Kg &amp; 3mg/Kg with epinephrine), single injection sonar guided.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracic paravertebral block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Ultrasound guided quadratus lumborum block</intervention_name>
    <description>prospective randomized comparative study between Group (1) : quadratus lumborum block</description>
    <arm_group_label>Quadratus lumborum block</arm_group_label>
    <other_name>QLB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Ultrasound guided thoracic paravertebral block</intervention_name>
    <description>PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.</description>
    <arm_group_label>Thoracic paravertebral block</arm_group_label>
    <other_name>PVB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion criteria&#xD;
&#xD;
          1. ASA I-III.&#xD;
&#xD;
          2. Age ≥ 20 &amp; ≤ 70&#xD;
&#xD;
          3. Body mass index (BMI): Less than forty and more than twenty.&#xD;
&#xD;
          4. Patients undergoing major gynacological cancer surgeries.&#xD;
&#xD;
        2. Exclusion criteria&#xD;
&#xD;
          1. Patient refusal.&#xD;
&#xD;
          2. History of sensitivity to local anesthetic (amide group).&#xD;
&#xD;
          3. History of psychological disorders.&#xD;
&#xD;
          4. Coagulopathies: hereditary (e.g. hemophilia, fibrinogen abnormalities&amp; deficiency of&#xD;
             factor II) - acquired (e.g. liver disease, vitamin K deficiency &amp; therapeutic&#xD;
             anticoagulants drugs).&#xD;
&#xD;
          5. Localized infection.&#xD;
&#xD;
          6. Morbid obese BMI&gt;40.&#xD;
&#xD;
          7. Incooperative patients.&#xD;
&#xD;
          8. Patients on chronic pain therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khaled A El-samahy, Professor</last_name>
    <role>Study Director</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ekramy M Abd-elghaffar, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esam Ab Mahran, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatma G Hussein, master</last_name>
    <phone>00201023431090</phone>
    <email>fatmagomaa54p@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Ueshima H, Otake H, Lin JA. Ultrasound-Guided Quadratus Lumborum Block: An Updated Review of Anatomy and Techniques. Biomed Res Int. 2017;2017:2752876. doi: 10.1155/2017/2752876. Epub 2017 Jan 3. Review.</citation>
    <PMID>28154824</PMID>
  </reference>
  <reference>
    <citation>Blanco R, Ansari T, Riad W, Shetty N. Quadratus Lumborum Block Versus Transversus Abdominis Plane Block for Postoperative Pain After Cesarean Delivery: A Randomized Controlled Trial. Reg Anesth Pain Med. 2016 Nov/Dec;41(6):757-762. Erratum in: Reg Anesth Pain Med. 2018;43:111.</citation>
    <PMID>27755488</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Fatma Gomaa Hussein</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Quadratus lumborum block</keyword>
  <keyword>Thoracic paravertebral block</keyword>
  <keyword>Postoperative analgesia</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Starting in April 2021 Ending in July 2021</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Immediately after publication No end date</ipd_time_frame>
    <ipd_access_criteria>Any one who wishes to access the data</ipd_access_criteria>
    <ipd_url>http://www.scopus.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

